Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
eczema
Biotech
Apollo $15M bet on IL-18 antibody pays off with ph. 2 eczema win
Apollo’s $15 million bet on Avalo’s anti-IL-18 monoclonal antibody appears to have paid off after the candidate aced a dermatitis trial.
James Waldron
Sep 16, 2025 9:50am
Sanofi phase 3 eczema win falls below analyst expectations
Sep 4, 2025 4:46am
Apogee claims IL-13 antibody sets new eczema treatment standard
Jul 7, 2025 8:29am
Leo's eczema prospect hits primary endpoint in phase 2b
May 9, 2025 7:30am
Amgen ignites Rocket program with wins in phase 3 eczema trials
Mar 10, 2025 5:48am
Anaptys scraps atopic dermatitis asset after ph. 2 fail
Dec 11, 2024 11:02am